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Context: Short sleep duration and poor sleep quality are associatedwith cardiovascular outcomes.
One mechanism proposed to explain this association is altered diurnal cortisol secretion.
Objective: The objective of the study was to examine the associations of sleep duration and sleep
quality with diurnal salivary cortisol levels.
Design: This was a cross-sectional analysis using data from examination 5 (2010–2012) of the
Multi-Ethnic Study of Atherosclerosis. Actigraphy-basedmeasures of sleep duration and efficiency
were collected over 7 days, and salivary cortisol samples were collected over 2 days from partici-
pants aged 54–93 years (n ! 600 with analyzable data).
Results: Shorter average sleep duration ("6 h/night) was associated with less pronounced late decline in
cortisol [2.2%difference inslope;95%confidence interval (CI)0.8–3.7;P! .01]and lesspronouncedwake-
to-bedslope(2.2%difference;95%CI1.0–3.4;P! .001)comparedwithlongersleepduration("6h/night).
Lower sleepefficiency ("85%)was associatedwith less pronouncedearly decline in cortisol (29.0%differ-
ence in slope; 95%CI 4.1–59.7; P" .05) comparedwith higher sleep efficiency ("85%). Subjects reporting
insomniahadaflattercortisolawakeningresponse(#16.1%difference inslope;95%CI#34.6to#0.1;P"
.05) comparedwith those not reporting insomnia.
Conclusions: Shorter sleep duration, lower sleep efficiency, and insomnia are associated with
alterations in diurnal cortisol levels consistent with changes in hypothalamic-pituitary-adrenal
regulation. (J Clin Endocrinol Metab 100: 3149–3158, 2015)
The impact of sleep duration and sleep quality on healthis widely recognized. Short sleep duration and poor
sleep quality have been linked to coronary heart disease
(1), cardiovascular disease (CVD) (2), and CVD risk fac-
tors (3). Short sleepdurationhas alsobeen linked tohigher
risk of subclinical CVD (4). Insomnia is also associated
with a higher risk of coronary heart disease (5) and CVD
mortality (6).
One potential mechanistic link between sleep and
health outcomes involves alteration of the function of the
hypothalamic-pituitary-adrenal (HPA) axis with conse-
quences for cortisol levels over the day. Diurnal cortisol
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exhibits a marked circadian pattern, with an early morn-
ing peak within the first 30 minutes after awakening
termed the cortisol awakening response (CAR) (7). The
CAR is followed by a steep decline during 2 hours after
awakening (early decline) and then a slow decline over the
restof theday (eveningdecline) (8). Studiesof theassociation
between sleep duration and/or sleep quality andmeasures of
diurnal cortisol have been inconsistent. Small experimental
studies in healthy young volunteers found increased evening
cortisol (9), decreased nighttime cortisol (10), or no CAR
changes after sleep deprivation or disturbance (11). Obser-
vational studies have also been inconclusive. For example,
short sleep durationwas associatedwith increasedCARand
shallower slope in cortisol (12), and poor sleep quality was
associated with shallower slope in cortisol (12, 13). How-
ever, other observational studies found no association (14,
15). Dysregulation of the HPA has also been linked to dia-
betes (16), obesity (17), postpartum depression (18), and
posttraumatic stress disorder (19).
Short sleep duration may also be associated with ad-
verse cardiometabolic outcomes when accompanied by
insomnia symptoms (20). For example, the joint presence
of insomnia and short sleep duration has been linked to
higher risk of hypertension (21). However, the relation-
ship between insomnia and cortisol has been investigated
inonly a fewsmall studies and the findings are inconsistent
(22–25).
Limitations of prior studies include lack of objective
measures of sleep duration and quality and limited sam-
pling of cortisol levels across the day. We hypothesized
that participants with short sleep duration or poor sleep
quality would have less pronounced CAR and shallower
cortisol decline during theday than thosewith longer sleep
duration or good sleep quality. We further hypothesized
that short sleep duration may be associated with cortisol
alterations only when insomnia is present.
Materials and Methods
Participants
The Multi-Ethnic Study of Atherosclerosis (MESA) is a lon-
gitudinal study designed to investigate risk factors for subclinical
CVD. In 2000–2002,MESA recruited 6814 men and women to
MESA examination 1 (26). At recruitment, participants were
45–84 years old, free of clinical CVD, and included four racial/
ethnic groups (white, African-Americans, Asians, and Hispan-
ics) from six US communities. Recruitment used several popu-
lation-based approaches, including lists of area of residents, area
residents enrolled in a union health plan, random digit dialing,
and lists from the Centers for Medicare and Medicaid Services
(27). MESA was approved by the institutional review board at
each field centers, and all participants gave written informed
consent.
The MESA Stress ancillary study enrolled 1082 MESA par-
ticipants at the New York, Los Angeles, and Baltimore field
centers duringMESAexamination5 (2010–2012). Trained staff
instructed participants to collect eight saliva samples per day for
2 successive days (directly on waking; 30 min after waking; 1 h
after finishing breakfast; 10:00 AM; 12:00 PM or before lunch,
whichever was earlier; 4:00 PM; 6:00 PM or before dinner, which-
ever was earlier; and at bedtime). Participants were instructed to
record the exact time of sample collection. Salivary samples were
stored at #20°C until analysis. Salivary cortisol level was deter-
mined using a commercially available chemiluminescence assay
with high sensitivity (0.16 ng/mL) (IBL-Hamburg). Intra- and in-
terassay coefficients of variation for the assay were less than 8%.
The MESA Sleep Study was a second ancillary study also
conducted at examination 5. Exclusionswere use of oral airways
supportdevices, nocturnal oxygenornightly continuouspositive
airway pressure. The protocol included 1-night home polysom-
nography, 7-day actigraphy (Actiwatch Spectrum; Philips Re-
spironics) together with a sleep diary and a sleep questionnaire.
Theactigraph senses signals generatedbymovementsof thewrist
and translates them into activity counts, which are gathered con-
tinuously and stored into epochs of 1 minute. Actigraphic data
during 30-second epochs were scored as sleep or wake by Acti-
ware-Sleep version 5.59 analysis software (MiniMitter Co, Inc).
A validated algorithm (28) was used to yield the final activity
count for each epoch. Intrascorer intraclass correlation coeffi-
cients for average sleep duration and sleep efficiency were 0.91
and 0.97.
At the three MESA Stress field centers, 622 subjects partici-
pated in the sleep study. Of these, 11 participants with less than
3 hours/night and 11 participants with 9 or more hours/night
average sleep duration were excluded. Our final sample com-
prised 600 participants.
Outcome variables
The daily cortisol profile was characterized using up to 16
measures of cortisol per participant. The variables derived were
cortisol awakening level, CAR, early decline, and late decline
(Figure 1). Additionally, we used two standard summary mea-
sures of cortisol: the wake-to-bed slope and area under the curve
(AUC) for a 16-hour day.
Figure 1. Short sleepers had lower cortisol at awakening and at 30
minutes after as well as slower decline later in the day and higher
levels of cortisol at bedtime than longer sleepers.
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Exposure variables
Sleep variables were averaged across all nights that the acti-
graph was worn. Sleep duration was defined as the average du-
rationof sleepbetween sleeponset (sleep start time) andmorning
wakening (sleep end time)while inbedafter lights off.Total sleep
timewas defined as the average duration inminutes of sleep time
during in-bed intervals and calculated by taking the sum of all
time asleep across the recording anddividing by the total number
of main sleep periods. Sleep duration was estimated as a contin-
uous variable (range3 to"9h); in addition, less than6hourswas
defined as short sleep. Sleep efficiency, an objective measure of
sleep quality, was defined as the percentage of time in bed after
lights off spent sleeping. Sleep efficiencywas calculatedby taking
the sum of all sleep time divided by the sum of all in bedtime
during main sleep intervals across the recording and multiplied
by 100 to obtain a percentage. Sleep efficiency was analyzed as
a continuous variable; in addition, less than 85%was defined as
poor quality.
Insomnia, a subjective measure of sleep quality, was assessed
based on self-report using theWomen’s Health Initiative Insom-
niaRating Scale (WHIIRS), a five-itemquestionnaire designed to
evaluate insomnia symptoms. The summary score ranged from
0 to 20. A score of 9 or more is considered clinically significant
insomnia (29).
Covariates at MESA examination 5
Age, sex, race/ethnicity, awakening time, income-wealth in-
dex (27), smoking status, alcohol consumption, body mass in-
dex, and depression using the 20-item Center for Epidemiology
Studies-Depression (CES-D) scale were examined. CES-D score
range is 0–60, with a higher score indicating more symptoms
(30). Depression was defined as CESD of 16 or greater (31).
Other covariates were diabetes, hypertension and use of medi-
cations for sleep and/or mood, oral and inhaled steroids, and
hormone replacement therapy. The apnea hypopnea index was
derived fromthepolysomnographyandwasdefinedas all apneas
plus hypopneaswith a 3%or greater desaturation or an arousal.
Analysis
A total of 8985 salivary samples were included in the analysis
after excluding samples with no time of collection, insufficient
sample for assay, or unreliable cortisol value (0 or$100 nmol/L)
(163 samples excluded). Differences in cortisol variables and
covariates by categories of sleep duration and sleep efficiency
were evaluated by an ANOVA, the Kruskall Wallis test, or #2
test. Cortisol was transformed using the natural logarithm be-
cause of skewed distribution. We examined the shape of the
diurnal cortisol profile (Figure 1) using locally estimated scatter
plot smoothing.
Associations of sleepmeasureswith features of the daily cortisol
curvewere examined using piecewise linear regressionmixedmod-
els (32).We used linear regression splineswith knots at 30 and 120
minutes after wake-up to capture the inflections of the diurnal cor-
tisol profile. Analyses of sleep duration and sleep quality were per-
formed using both categorical and continuous measures.
Model 1 included adjustment for time of wake-up, first vs
secondday of salivary collection, age, gender, race/ethnicity, and
income-wealth index. Model 2 was additionally adjusted for
body mass index, smoking, alcohol consumption, medications,
and apnea hypopnea index. Model 3 additionally included hy-
pertension, diabetes, and depression.Model 4 for sleep duration
included covariates in model 3 plus sleep efficiency; for sleep
efficiency as the predictor, model 4 included sleep duration as a
covariate; and for insomnia as the predictor, model 4 included
sleep efficiency as a covariate. All covariates were entered as
main effects and also as two-way interaction terms with the
three-spline pieces. Coefficients and their confidence intervals
obtained from the models were exponentiated to be interpreted
as percentage differences between categories of the predictor
variable.
We also estimated the wake-to-bed slope, which is the slope
of the decline of cortisol between wake-up and bedtime, and the
AUCfor a16-hourday.Bothmeasureswere estimatedwithin the
mixed model.
We explored effect modification using stratified analyses to
study the role of insomnia in the association of sleep duration
with alterations in the diurnal cortisol level. A test for interaction
between insomnia symptoms and sleep duration was used to test
whether the association of sleep duration with cortisol differed be-
tween subjects with and without insomnia. We first examined
whether the insomnia covariate was statistically significant with
P" .2, and thenwe included in themodel themain effect, two-way
interactionswith the three spline pieces, and three-way interactions
(insomnia, sleep duration, each of the three spline pieces).
We performed secondary analyses in which we restricted our
sample to participants younger than 75 years, to those without
depression, to nonusers of antidepressants, to nonusers of oral/
inhaled steroids, and to participants with an apnea hypopnea
index of less than 15 (without moderate or severe sleep apnea).
We also investigated alternative cut points for sleep duration and
sleep efficiency.
Results
Table 1 shows summary characteristics for the 600 par-
ticipants included in the analyses.Our overall sample con-
sisted of 316 women (53%) and 284 men (47%) from
three different race/ethnic backgrounds: Hispanic (40%),
African-American (32%), and white (28%). Mean age
was 69.2 % 9 years.
Sleep duration
Participant characteristics according to sleep duration
less than6hours (n!202) and6hours or longer (n!398)
are shown in Tables 1 and 2. The median (interquartiles:
Q1–Q3) evening cortisol (at bedtime) was higher among
short sleepers (3.6 nmol/L, 2.1–7.0) comparedwith longer
sleepers (3.3 nmol/L, 1.9–5.3; P ! .03). The normal me-
dian for the evening cortisol in this assay is approximately
2.0 nmol/L (10th percentile of 0.1 to 90th percentile of
6.0). Men, African-Americans, low-income participants,
and participants who were obese, diabetic, used inhaled
steroids, or had low sleep efficiency had lower average
sleep duration than their counterparts (Supplemental Ta-
ble 1). Figure 1 shows locally estimated scatter plot
smoothing curves for the daily cortisol profile stratified by
sleep duration.
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Table 3 (first column) shows percentage differences and
95% confidence intervals (CIs) between short and longer
sleep duration in features of the daily cortisol curve and the
wake-to-bed slope and AUC. Short sleep duration was as-
sociated with less pronounced late decline in all models
(model4,2.2%difference inslope;95%CI0.8–3.7;P! .01)
and with less pronounced wake-to-bed slope in all models
(model4,2.2%difference;95%CI1.0–3.4;P! .001).Short
sleepdurationwasnot associatedwithAUC.Consistentpat-
ternswere observedwhen sleep durationwas investigated as
a continuous variable (Supplemental Table 2, first column).
Sleep efficiency
Sleep efficiency ranged from 71.6% to 97.0%. Tables
1 and 2 show participant characteristics classified accord-
ing to sleep efficiency. There was no difference in the eve-
ning cortisol between those participants with low vs
higher sleep efficiency.
Low sleep efficiency was associated with less pro-
nounced early decline in all models (model 4, 29.0% dif-
ference in slope; 95% CI 4.1–59.7; P ! .05) (Table 3).
Sleep efficiency was not associated with the wake-to-bed
slope or AUC. Consistent patterns were observed when
sleep efficiency was investigated as a continuous variable
(Supplemental Table 2, second column).
Insomnia
In the analytical sample, 209 participants (35%) re-
ported insomnia symptoms (Supplemental Table 3). This
group was more likely to include women, to be in the
lowest categories of the income-wealth index, and to re-
port higher scores of depression symptoms and hostility
compared with those without insomnia symptoms.
Table 4 shows the associations between insomnia and
cortisol levels in the full sample and stratified by short vs
longer sleep duration. Overall, insomnia was associated
with less pronouncedCAR inmodels 1, 2, and 4 (model 4,
#16.1% difference; 95% CI #34.6 to #0.1; P " .05)
(Table 4, first column). In the subsample of short sleepers,
insomnia was associated with less pronounced CAR com-
Table 1. Demographic and Clinical Characteristics of Participants (n ! 600) by Sleep Duration and Sleep Efficiency,
MESA Study (2010–2012)
Sleep Duration (hours) Sleep Efficiency (%)








(n " 540) P Value*
Demographics
Age, y 68.6 % 9.0 69.4 % 9.0 .31 70.3 % 7.4 69.0 % 9.2 .21
Male 106 (53) 178 (45) .07 35 (58) 249 (46) .07
Race/ethnicity ".0001 .17
White 36 (18) 130 (33) 11 (18) 155 (29)
Black 92 (45) 99 (25) 24 (40) 167 (31)
Hispanic 74 (37) 169 (42) 25 (42) 218 (40)
Income-wealth index .14 .03
0–1 33 (18) 41 (12) 12 (21) 62 (13)
2–3 41 (22) 83 (24) 5 (9) 119 (25)
4–6 80 (43) 142 (41) 28 (49) 194 (41)
7–8 33 (18) 83 (24) 12 (21) 104 (22)
Married 98 (50) 230 (59) .05 35 (59) 293 (56) .57
Lifestyle characteristics
Body mass index 30.6 (5.7) 28.9 (5.0) ".001 30.7 (6.2) 29.3 (5.2) .05
Smoking status .05 .28
Current 23 (11) 25 (6) 4 (7) 44 (8)
Former and quit $1 y ago 66 (33) 156 (39) 28 (47) 194 (36)
Never 112 (56) 215 (54) 28 (47) 299 (56)
Alcohol consumption 75 (37) 164 (41) .36 23 (38) 216 (40) .79
Hypertension 127 (63) 231 (58) .25 37 (62) 321 (59) .74
Diabetes 83 (41) 165 (42) .91 30 (50) 218 (41) .16
Depression CES-D $16 39 (20) 58 (15) .12 11 (19) 86 (16) .63
Oral steroid users 3 (2) 5 (1) .82 2 (3) 6 (1) .15
Inhaled steroid users 11 (6) 4 (1) ".001 2 (3) 13 (2) .66
Antihypertensive users 122 (60) 218 (55) .19 35 (58) 305 (57) .78
HRT users 4 (2) 14 (4) .30 0 (0) 18 (3) .15
Antidepressant users 17 (8) 49 (12) .15 6 (10) 60 (11) .79
Abbreviation: HRT, hormone replacement therapy.
* Either #2 or t test/ANOVA or Kruskall Wallis test for variables nonnormally distributed.
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paredwith thosewithout insomnia in allmodels (model 4,
#37.7% difference; 95% CI #79.4 to #5.7; P " .05)
(Table 4, second column). In the subsample of longer
sleepers, insomnia was associated with only a more pro-
nounced late decline in cortisol comparedwith thosewith-
out insomnia in all models (Table 4, third column).
We also compared the association between sleep dura-
tion and salivary cortisol in participants with andwithout
insomnia. In the group with insomnia (Table 5, first col-
umn), short sleep duration was associated with less pro-
nouncedCAR inmodels 3 and4 andwith less pronounced
late decline in cortisol in all models (model 4, 3.6% dif-
ference in slope; 95%CI 1.2–6.0;P! .01) comparedwith
longer sleep duration. This was not observed in the group
without insomnia (Table 5, second column). Both the
groups with and without insomnia showed less steepness
in the wake-to-bed cortisol slope in those with short vs
longer sleep duration (Table 5). The statistical test for
interaction between insomnia and sleep duration was of
marginal significance (P for interaction ! .1).
Secondary analyses
Participants with depression represented 17% of our
sample (n ! 600). Only the second sample of salivary
cortisol (taken 30 min after awake) was different among
those who had CES-D of 16 or greater (median 18.9
nmol/L, Q1–Q3! 12.8–28.9) compared with those with
CES-D less than16 (median22.3 nmol/L,Q1–Q3!15.5–
31.5) (Supplemental Table 4). Salivary cortisol level did
not differ between participants with depression taking an-
tidepressants compared with those who were not or be-
tween those with hypertension or diabetes comparedwith
those without hypertension or diabetes.
Results of analyses restricted to participants younger
than 75 years old, those without depression, nonusers of
antidepressants, nonusers of oral/inhaled steroids, and
participants without moderate sleep apnea were not ma-
terially different from the unrestricted analyses. Analyses
using 7 hours (n! 399) as the cut point for short vs longer
sleep duration did not differ materially from analyses us-
ing6hours as the cutpoint, but analysesusing5hours (n!
69) as the cut point differed in that point estimates were
lower than those using 6 hours as the cut point and did not
reach statistical significance (Supplemental Table 5). For
sleep efficiency, very few participants would have been
categorized as poor sleeper for cut points lower than 85%.
Finally, our results did not differ from the unrestricted
samplewhenweexcludedparticipantswith sleepduration
between 8 and 9 hours (n ! 53) (Supplemental Table 6).
Discussion
In this population-based study of adults, using multiple
measures of salivary cortisol and objective in-home sleep
data, we found that sleep duration and sleep quality were
Table 2. Sleep Characteristics and Diurnal Cortisol Values of Participants (n ! 600) by Sleep Duration and Sleep
Efficiency, MESA Study (2010–2012)
Sleep Variables
Sleep Duration, h Sleep Efficiency, %








(n " 540) P Value*
Any insomnia symptoma 75 (38) 134 (34) .36 24 (41) 185 (35) .37
Sleep efficiency, %
Low ("85%) 32 (16) 28 (7) ".001 NA NA
Sleep duration
Short ("6 h) NA NA 28 (47) 370 (69) ".001
Apnea hypopnea index "15b 109 (63) 214 (58) .34 39 (72) 284 (58) ".05
Cortisol measures, median
(Q1–Q3), nmol/L
Wake-up 15.2 (10.0–20.5) 16.5 (11.4–24.4) .02 13.9 (7.1–19.8) 16.2 (11.2–22.9) .02
30 min later 19.7 (12.0–29.4) 23.7 (15.7–31.9) .006 17.4 (11.3–29.0) 22.9 (15.2–31.6) .01
1 h after breakfast 11.6 (8.0–16.5) 11.4 (8.4–16.4) .90 11.7 (8.6–15.0) 11.4 (8.2–16.5) .84
10:00 AM 8.8 (6.2–12.3) 9.0 (6.6–13.1) .21 8.9 (6.5–14.5) 9.0 (6.5–12.5) .74
Noon 7.7 (5.0–11.3) 7.5 (5.3–10.5) .62 7.0 (5.0–11.9) 7.6 (5.2–10.6) .95
4:00 PM 5.6 (3.7–9.1) 5.5 (3.6–8.2) .83 5.7 (3.4–8.7) 5.5 (3.7–8.3) .90
6:00 PM 4.2 (2.8–6.6) 4.1 (2.6–6.6) .77 4.3 (2.5–7.0) 4.1 (2.7–6.4) .86
Bedtime 3.6 (2.1–7.0) 3.3 (1.9–5.3) .03 3.1 (1.8–5.5) 3.4 (2.0–5.8) .64
* Either #2 or t test/ANOVA or Kruskall Wallis test for variables nonnormally distributed.
a Assessed by WHIIRS score of 9 or greater is insomnia.
b Apnea [all apneas and hypopnea per hour of the sleep with "3% desaturation # index (apnea hypopnea index)].
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associatedwith alterations of the diurnal cortisol patterns.
Notably, short sleep duration was associated with less
pronounced late decline in cortisol and less pronounced
wake-to-bed slope. These associations remained signifi-
cant after adjustment for sleep apnea, sleep efficiency, and
other covariates and were robust to various sensitivity
analyses. The flatter late cortisol decline associated with
short sleep duration could be attributable to either low
awaking cortisol level or high evening cortisol level. How-
ever, we found no association of short sleep durationwith
awakening cortisol level, suggesting that changes in
wake-up level did not account for these slope differences.
Poor sleep quality, measured objectively with actigraphy
and characterized as sleep efficiency or assessed subjec-
tively as insomnia, also were associated with less pro-
nounced early cortisol decline. In stratified analyses, we
found some evidence that associations of sleep duration
with diurnal salivary cortisol were stronger among study
Table 3. Percentage Differences (95% CIs) in Features of the Daily Cortisol (Wake-Up, CAR, Early Decline, and Late
Decline) and Summary Measures of Cortisol (Wake to Bed Slope and AUC) Associated With Sleep Duration and Sleep
Efficiency
Sleep Durationa
(<6 h vs >6 to <9 h)
Sleep Efficiencyb
(<85% vs >85%)
Percentage difference in wake-up
Model 1c #11.93 (#30.9, 4.3) #33.73 (#81.5, 1.5)
Model 2d #12.57 (#34.4, 5.7) #37.91 (#93.8, 1.8)
Model 3e #10.95 (#33.0, 7.4) #39.44 (#97.4, 1.5)
Model 4f #8.20 (#29.1, 9.3) #36.98 (#93.5, 3.0)
Percentage difference in CAR
Model 1c #8.70 (#25.2, 5.6) #2.00 (#27.6, 18.47)
Model 2d #8.16 (#26.6, 7.6) 0.29 (#21.9, 28.7)
Model 3e #9.40 (#28.5, 6.9) 0.09 (#22.2, 28.8)
Model 4f #9.57 (#27.9, 6.1) 2.35 (#20.1, 31.0)
Percentage difference in early decline
Model 1c 6.34 (#5.0, 19.0) 22.12 (0.7, 48.2)g
Model 2d 6.02 (#6.4, 20.0) 25.97 (2.8, 54.4)g
Model 3e 5.28 (#7.3, 19.6) 27.65 (3.7, 57.2)g
Model 4f 2.35 (#9.7, 15.9) 28.96 (4.1, 59.7)g
Percentage difference in late decline
Model 1c 1.86 (0.6, 3.1)h #0.85 (#2.7, 1.0)
Model 2d 2.02 (0.7, 3.4)h #1.05 (#3.2, 1.0)
Model 3e 2.05 (0.7, 3.5)h #0.98 (#3.1, 1.1)
Model 4f 2.23 (0.8, 3.7)h #1.84 (#4.2, 0.4)
Summary measures of cortisol
Percentage difference in wake-to-bed slope
Model 1c 2.15 (1.1, 3.2)i 0.45 (#1.2, 2.1)
Model 2d 2.33 (1.2, 3.5)i 0.59 (#1.2, 2.4)
Model 3e 2.27 (1.1, 3.5)i 0.75 (#1.0, 2. 6)
Model 4f 2.22 (1.0, 3.4)j 0.06 (#1.8, 1.9)
Percentage difference in AUC
Model 1c 0.34 (#10.6, 12.7) #8.97 (#32.6, 10.5)
Model 2d 0.77 (#11.4, 14.9) #6.56 (#32.8, 14.5)
Model 3e 0.28 (#12.1, 14.5) #5.51 (#32.2, 15.8)
Model 4f #0.15 (#14.6, 12.5) #5.28 (#32.8, 16.6)
Bold values indicate significance.
a Sleep duration was estimated as dichotomized [short sleep duration (3 to "6 h)] vs longer (reference "6 h to "9 h).
b Sleep efficiency was estimated as dichotomized [low sleep efficiency ("85%)] vs high (reference "85%).
c Model 1: model adjusted for day of salivary collection, time of wake-up, gender, age, race/ethnicity, and income-wealth index.
d Model 2: model 1 & body mass index, smoking, alcohol consumption, medications (oral and inhaled steroids, hormone replacement therapy,
sleep medication, and antidepressants) and apnea hypopnea index.
e Model 3: model 2 & hypertension, diabetes, and depression.
f Model 4: model 3 & sleep efficiency (as continuous) or sleep duration (as continuous) in models for sleep duration and sleep efficiency,
respectively.
g P " .05.
h P ! .01.
i P ! .0001.
j P ! .001.
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participants who also reported insomnia symptoms than
among those who did not. The test for interaction was of
marginal statistical significance. We did not find associa-
tions of sleep characteristics with AUC, suggesting that
this summary measure may be less sensitive to sleep-asso-
ciated alterations in the diurnal cortisol profile than spe-
cific components examined using the piecewise linear
mixed models.
Only a few population-based studies have examined
associations of sleep with daily cortisol profile. These
studies used self-reported measures of sleep duration and
sleep efficiency. However, discrepancies between self-re-
ported and objective measures of sleep have been de-
scribed, especially in large, well-conducted community
studies (33, 34). The Whitehall II Study (12), with 2751
participants, collected up to six salivary cortisol samples
and self-reported sleep duration and quality. That study
found that short sleep duration was associated with in-
creasedCARand shallower slope in cortisol and that sleep
disturbance was associated with shallower slope in corti-
Table 4. Percentage Differences (95% CIs) in Features of the Daily Cortisol (Wake-Up, CAR, Early Decline, and Late
Decline) and Summary Measures of Cortisol (Wake to Bed Slope and AUC) Associated With Insomnia and Stratified
by Short and Longer Sleepers
Insomnia vs Noninsomniaa
Overall Sample





Percentage difference in wake-up
Model 1c 8.28 (#5.9, 24.7) 5.43 (#17.5, 34.8) 11.17 (#6.6, 32.3)
Model 2d 6.40 (#8.7, 24.0) 9.40 (#17.5, 45.1) 7.10 (#10.7, 28.5)
Model 3e 5.70 (#9.5, 23.5) 7.63 (#19.4, 43.8) 7.85 (#10.1, 29.3)
Model 4f 6.97 (#8.6, 25.2) 10.86 (#16.9, 47.9) 8.18 (#10.0, 30.0)
Percentage difference in CAR
Model 1c #18.73 (#36.1, #3.5)g #38.86 (#77.5, #8.6)g #8.30 (#27.2, 7.8)
Model 2d #16.43 (#35.0, #0.4)h #33.40 (#76.17, #1.0)h #7.12 (#27.2, 9.8)
Model 3e #15.90 (#34.8, 0.3) #36.53 (#80.5, #3.3)h #5.90 (#25.2, 10.4)
Model 4f #16.11 (#34.6, #0.1)h #37.74 (#79.4, #5.7)h #5.90 (#25.4, 10.6)
Percentage difference in early decline
Model 1c 11.44 (0.7, 23.3)h 15.85 (#4.6, 40.7) 9.75 (#2.3, 23.3)
Model 2d 9.87 (#1.17, 22.2) 9.90 (#11.5, 36.4) 9.76 (#2.7, 23.8)
Model 3e 8.65 (#2.7, 21.3) 9.31 (#12.5, 36.5) 8.80 (#4.1, 21.8)
Model 4f 7.52 (–3.5, 19.8) 6.12 (-13.9, 30.9) 7.80 (#4.3, 21.5)
Percentage difference in late decline
Model 1c #1.05 (#2.3, 0.2) 0.22 (#1.9, 2.4) #2.02 (#3.4, #0.7)g
Model 2d #1.06 (#2.4, 0.2) 0.35 (#2.0, 2.7) #2.01 (#3.5, #0.7)g
Model 3e #1.12 (#2.5, 0.2) 0.53 (#1.8, 2.9) #2.19 (#3.7, #0.7)g
Model 4f #1.09 (#2.4, 0.2) 0.91 (#1.4, 3.3) #2.27 (#3.7, #0.8)g
Summary measures of cortisol
Percentage difference in wake-to-bed slope
Model 1c #0.60 (#1.6, 0.4) 0.17 (#1.7, 2.1) #1.20 (#2.5, #0.1)h
Model 2d #0.67 (#1.8, 0.4) #0.07 (#2.2, 2.0) #1.20 (#2.3, #0.1)h
Model 3e #0. 78 (#1.9, 0.3) 0.07 (#2.0, 2.2) #1.38 (#2.5, #0.3)g
Model 4f #0.86 (#2.0, 0.3) 0.14 (#2.0, 2.3) #1.52 (#2.6, #0.4)g
Percentage difference in AUC
Model 1c #0.38 (#11.4, 9.6) #5.45 (#30.2, 14.6) 3.40 (#8.0, 16.2)
Model 2d #2.26 (#14.4, 8.6) #4.31 (#30.9, 16.9) 0.47 (#11.1, 13.6)
Model 3e #4.43 (#17.3, 7.0) #8.07 (#35.7, 13.9) #0.60 (#14.3, 11.5)
Model 4f #4.66 (#17.7, 6.9) #7.77 (#35.5, 14.3) #1.17 (#15.2, 11.2)
Bold values indicate significance.
a Insomnia symptoms WHIIRS [insomnia (score "9) vs noninsomnia (reference, score "9)].
b Sleep efficiency at 85% cutoff [low sleep efficiency ("85%) vs higher sleep efficiency (reference, "85%)].
c Model 1: model adjusted for day of salivary collection, time of wake-up, gender, age, race/ethnicity, and income-wealth index.
d Model 2: model 1 & body mass index, smoking, alcohol consumption, and medications (oral and inhaled steroids, hormone replacement
therapy, sleep medication, and antidepressants) and apneas and hypopneas index.
e Model 3: model 2 & hypertension, diabetes, and depression.
f Model 4 (for insomnia): model 3 & sleep efficiency.
g P ! .01.
h P " .05.
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sol. Our findings are consistent with the Whitehall find-
ings in that short sleep duration was associated with less
pronounced diurnal cortisol decline; however, we did not
find an association between short sleep and increased
CAR. The Whitehall study differed from our study in
that the population was younger, healthier, and less
racially diverse. A Danish study (13) of mostly young
women (n ! 4060) with salivary samples at two points
in the day and self-reported sleep duration and quality
did not find associations between sleep duration and
cortisol but did find associations between sleep prob-
lems and lower morning cortisol. This study also found
associations between poor sleep quality and less pro-
nounced decline in cortisol in a subsample. We also
found that poor sleep quality was associated with less
pronounced early decline in cortisol. Other observa-
tional studies found no associations. Although these
studies used objective measures of sleep duration and
Table 5. Percentage Differences (95% CIs) in Features of the Daily Cortisol (Wake-Up, CAR, Early Decline, and Late
Decline) and Summary Measures of Cortisol (Wake to Bed Slope and AUC) Associated With Sleep Duration Stratified
by Insomnia Symptomsa
Sleep Duration, Dichotomizedb (Reference,
>6 h of sleep)
With Insomnia (n " 209) Without Insomnia (n " 382)
Percentage difference in wake-up
Model 1c #13.43 (#38.7, 7.2) #10.65 (#37.6, 11.0)
Model 2d #14.49 (#40.5, 6.7) #15.93 (#48.1, 9.2)
Model 3e #10.21 (#36.0, 10.7) #14.34 (#46.9, 11.0)
Model 4f #8.39 (#34.1, 12.4) #10.71 (#41.5, 13.4)
Percentage difference in CAR
Model 1c #28.43 (#68.4, 2.0) 0.97 (#13.9, 18.4)
Model 2d #26.65 (#71.7, 6.6) 2.21 (#14.6, 22.4)
Model 3e #36.89 (#85.5, #1.0)g 2.98 (#13.9, 23.2)
Model 4f #31.93 (#71.5, #1.5)g 0.16 (#16.9, 20.8)
Percentage difference in early decline
Model 1c 5.48 (#13.5, 28.7) 3.89 (#9.1, 19.3)
Model 2d 3.70 (#16.5, 28.8) 6.12 (#9.0, 23.7)
Model 3e 5.65 (#15.7, 32.5) 5.12 (#9.7, 22.4)
Model 4f 2.29 (#16.6, 25.5) 3.11 (#11.8, 20.6)
Percentage difference in late decline
Model 1c 3.39 (1.2, 5.6)h 1.37 (#0.2, 2.9)
Model 2d 3.53 (1.3, 5.8)i 1.37 (#0.3, 3.1)
Model 3e 3.68 (1.4, 6.0)i 1.30 (#0.4, 3.0)
Model 4f 3.55 (1.2, 6.0)i 1.61 (#0.1, 3.4)
Summary measures of cortisol
Percentage difference in wake-to-bed slope
Model 1c 2.93 (1.0, 4.9)i 1.82 (0.5, 3.1)i
Model 2d 2.98 (1.1, 4.9)h 2.07 (0.7, 3.5)i
Model 3e 3.05 (1.0, 5.1)i 1.96 (0.6, 3.4)i
Model 4f 2.85 (1.0, 5.0)i 2.02 (0.6, 3.5)i
Percentage difference in AUC
Model 1c #9.87 (#31.4, 8.1) 4.54 (#10.4, 22.0)
Model 2d #11.12 (#33.8, 7.7) 4.00 (#12.5, 23.6)
Model 3e #11.51 (#34.8, 7.7) 4.43 (#12.2, 24.2)
Model 4f #11.40 (#34.9, 8.0) 4.10 (#13.0, 24.5)
Bold values indicate significance.
a Insomnia symptoms (WHIIRS), dichotomized as with insomnia (score "9) and without insomnia.
b Sleep duration was dichotomized [short sleep duration ("6 h)] vs longer (reference, "6 h to "9 h).
c Model 1: model adjusted for day of salivary collection, time of wake-up, gender, age, race/ethnicity, and income-wealth index.
d Model 2: model 1 & body mass index, smoking, alcohol consumption, medications (oral and inhaled steroids, hormone replacement therapy,
sleep medication, and antidepressants) and apnea hypopnea index.
e Model 3: model 2 & hypertension, diabetes, and depression.
f Model 4: model 3 & sleep efficiency (as continuous).
g P " .05.
h P ! .001
i P ! .01.
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quality, they used differentmeasures of cortisol. A study
from China (14) examined 96 study participants using
3-day actigraphy with awakening salivary cortisol and
found no association of salivary awakening cortisol
with sleep duration or sleep efficiency. In the Osteopo-
rotic Fractures in Men Study (15), actigraphy-based
sleep duration and 24-hour free urinary cortisol were
measured. No association between sleep duration and
urinary cortisol was found in this cohort of older men.
We found that in contrast to short sleep duration, in-
somnia was associated with a reduced CAR in the full
sample aswell as in the sample of short sleepers. Insomnia,
however,was associatedwithmore pronounced decline in
cortisol in the longer than the shorter sleepers.Other stud-
ies have reported that insomnia is associated with eleva-
tion of the evening cortisol (22, 23) or with lower awak-
ening cortisol (24). Further investigation is warranted to
address potential heterogeneity within individuals with
insomnia in regards to HPA axis measures.
Our findings showing associations of shorter sleep and
poorer sleep quality with a flatter cortisol decline over the
day are significant because other work has documented
that these types of alterations of the cortisol pattern are
related to health outcomes. For example in the MESA
study, lower CAR was associated with diabetes (16) and
less pronounced cortisol decline with obesity (17), and in
the Coronary Artery Risk Development in Young Adults
study, a flattened diurnal cortisol pattern was associated
with atherosclerosis (35). The largest study to examine the
association of diurnal cortisol profile with cardiovascular
disease-related mortality found that the slope in cortisol
across the day and bedtime cortisol predicted cardiovas-
cular-related mortality (36).
Our study has several limitations. First, our data are
cross-sectional. We approached the analysis a priori by
defining sleep duration and quality as the independent
variables and HPA axis measures as the dependent vari-
ables. Second, the sleep and cortisol data were collected
from each subject at a single point in time, and intraindi-
vidual variability over time was not captured. In the Cor-
onary Artery Risk Development in Young Adults study,
sleepdurationandefficiencymeasuredbyactigraphywere
relatively stable from year to year (37). The daily cortisol
profile also varies from day to day. The use of 2 consec-
utive days is therefore an advantage over single-day stud-
ies. InMESA, long-term stability over 6 years is moderate
(intraclass correlation 0.25 for the early decline and 0.42
for the late decline) (38). Variability in both sleep and
cortisol over timemayhave attenuated the estimates of the
true associations. Third, insomnia, a common clinically
recognized entity, may represent several subphenotypes,
with variable associations with depression, anxiety, and
other conditions. Further refinement of this clinical entity
could help clarify the associations between insomnia and
the HPA axis. The mean age of our sample at MESA ex-
amination 5 was 69.2 years. Studies suggest that age is
associated with elevated salivary cortisol in the evening
(39, 40), and we therefore adjusted all models for age.
Finally, power to assess associations with low sleep effi-
ciency was limited because only 10% of our sample had
sleep efficiency less than 85%.
Astrengthofour study is theavailabilityofhigh-quality
data for a variety of covariates including sleep apnea. Ex-
cept for one study (15), the studies mentioned above did
not adjust for this variable. A second strength is that we
used objectively measured assessments of sleep duration
and efficiency recorded over several nights. A third
strength is that we had up to 16 salivary samples over 2
days, allowing us to model the diurnal cortisol profile. A
fourth strength is a large, diverse, population-based
sample.
In summary, we found associations of shorter sleep du-
ration and worse sleep quality with alterations in features
of the diurnal cortisol profile. Whereas the alterations in
diurnal cortisol pattern that we observed in association
with sleep duration and quality are modest in magnitude,
when sustained over a long time period, these alterations
may contribute to the increased risk of cardiovascular dis-
ease that has been found in association with sleep
disturbances.
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